YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
(RTTNews) - Cardiff Oncology, Inc. (CRDF) a clinical-stage oncology company, reported second quarter results, reflecting a narrower loss primarily driven by lower operating expenses. The company in particular noted reduced Research and Dev…
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. At Cardiff Oncology, a filing with the SEC re…
Medical research ©kaboompics.com Cardiff Oncology has secured a $10 million registered direct offering, providing additional capital for working capital and general corporate purposes as the company continues advancing its lead oncology pr…
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Cardiff Oncology, Inc. (NASDAQ:CRDF) is one of the most promising stocks on our list. TheFly reported on June 5 that Lucid Capital analys…
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company manage…
[Health Care sector, stock exchange monitor with index information.] Torsten Asmus The semi-annual rebalancing of U.S. equities is officially underway after FTSE Russell unveiled its preliminary list of shifts for the broad-market Russell…
* Cardiff Oncology (CRDF [https://seekingalpha.com/symbol/CRDF]) on Thursday said it has appointed Mani Mohindru as President and Chief Executive Officer. * Mohindru, who was serving as the interim CEO of the company, will continue as a me…
Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive Officer Appoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief Operating Officer SAN DIEGO, April 09, 202…
- Getty Images/iStockphoto Certain stocks are good bets to lag the market in the coming months, according to a new study, regardless of what the market does. Sixteen of these stocks are listed in a table at the end of this column. Short se…
* Cardiff Oncology press release [https://seekingalpha.com/pr/20412173-cardiff-oncology-reports-full-year-2025-results-and-provides-business-update] (CRDF [https://seekingalpha.com/symbol/CRDF]): FY GAAP EPS of -$0.69 beats by $0.08. * Rev…
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company manage…
By John Vandermosten, CFA NASDAQ:CRDF READ THE FULL CRDF RESEARCH REPORT On January 27th, 2026, Cardiff Oncology, Inc. (NASDAQ:CRDF) announced that its CEO, Dr. Mark Erlander, and CFO, James Levine, stepped down from their roles. The new c…
The U.S. stock market has recently extended its gains, with major indices like the Dow Jones and Nasdaq showing positive momentum amid eased geopolitical tensions. In such a climate, investors often look beyond the well-known giants to exp…
NEW YORK, NY / ACCESS Newswire / December 9, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day Year-End Virtual Investor Conference taking place Wednesday…
By John Vandermosten, CFA NASDAQ:CRDF READ THE FULL CRDF RESEARCH REPORT We are initiating coverage of Cardiff Oncology, Inc. (NASDAQ:CRDF) with a valuation of $8.50 per share. This value is based on our estimates for successful developmen…
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data…
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company manage…
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company manage…
DelveInsight Business Research LLP The KRAS inhibitors market is expected to experience substantial growth, driven by rising cancer incidence, improved treatment access, and a robust pipeline including Olomorasib (Eli Lilly), MK-1084 (Merc…
– Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects to report an update from the Phase 2 CRDF-004…
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company manage…
(RTTNews) - Several healthcare and biotech stocks posted notable gains in after-hours trading on Monday, driven by earnings updates, executive appointments, and capital market activity. Pulmonx Corp. (LUNG) surged 33.33% to $2.08 as of 9:3…
SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company manage…
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company manage…
Investing.com - H.C. Wainwright has reduced its price target on Cardiff Oncology (NASDAQ:CRDF) to $10.00 from $18.00 while maintaining a Buy rating on the stock. Currently trading at $2.57, the clinical-stage biotech company has a market c…
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. At Cardiff Oncology, a filing with the SEC re…
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements. [topmovers] TOP GAINERS TICKER CHANGE COMMENT REPL [https://www.chartmill.com/stock/quote/REPL/profile] 95.47% REPLIMUNE GR…
Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] GAINERS TICKER CHANGE COMMENT REPL [https://www.chartmill.com/stock…
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday. [gap] TOP GAP UP STOCKS TICKER CHANGE COMMENT REPL [https://www.chartmill.com/stock/quote/REPL/profile] 70.91% In today…
As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] GAINERS TICKER CHANGE COMMENT REPL [https://www.chart…
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items. Th…
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT RCON [https://www.chartmill.com/stock/quote/RCON/profile] 23.45…
– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring 30mg onvansertib dose arm vs. control arm –…
(RTTNews) - Cardiff Oncology Inc. (CRDF), a clinical-stage biotechnology company, is expected to share additional clinical data from its ongoing CRDF-004 trial on July 29, 2025. CRDF-004 is a phase II trial evaluating the company's drug ca…
PALM BEACH, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions o…
Investing.com - Ladenburg Thalmann initiated coverage on Cardiff Oncology (NASDAQ:CRDF), currently trading at $3.65 with a market cap of $243 million, with a Buy rating and a $19.00 price target on Tuesday. According to InvestingPro data,…